ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1779

Gap in Contraceptive Education to Females with Rheumatic Disease on Teratogenic Medications
Abstract Number: 1780

Maternal and Fetal Outcomes in Pregnant Women with Psoriatic Arthritis: A Systematic Literature Review
Abstract Number: 1781

Pregnancy After Bariatric Surgery in Women with Rheumatic Diseases and Association with Adverse Birth Outcomes
Abstract Number: 1782

Use of a Patient-reported Survey to Document Contraceptive Use and Interest in Pregnancy to Identify Patients with Unmet Pregnancy Prevention and Planning Needs
Abstract Number: 1783

Experience of Pregnant Rheumatology Outpatients from a Tertiary Hospital in New York City During the COVID-19 Pandemic
Abstract Number: 1784

Roles and Perspectives of Partners of Women with Rheumatoid Arthritis on Reproductive Decision Making: A Constructivist Grounded Theory Study
Abstract Number: 1785

Use of Contraceptive Methods in Mexican Women with Rheumatic Diseases
Abstract Number: 1786

Reproductive Health Outcomes in Women with RA and PsA
Abstract Number: 1787

Differences in Chromatin Architecture Between Treatment Naïve Pediatric and Adult Lupus Patients
Abstract Number: 1788

Assessment of the Impact of Interferon Levels on Cognitive Dysfunction in Patients with SLE
Abstract Number: 1789

Time to Renal Insufficiency Based on 25(OH)-Vitamin D Levels
Abstract Number: 1790

Association of Telomere Length and the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) in Long Standing Systemic Lupus Erythematosus
Abstract Number: 1791

Renal Tubular Complement C9 Deposition Is Associated with Renal Tubular Damage and Fibrosis in Lupus Nephritis
Abstract Number: 1792

Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE
Abstract Number: 1793

Safety of Obtaining Research Tissue During Clinically Indicated Kidney Biopsies: Data from the Lupus Accelerating Medicines Partnership

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].